SkinBit's $6 Million Pre-Seed Funding Round
SkinBit, a health tech startup specializing in advanced imaging technology for skin analysis, has successfully raised $6 million in a pre-seed funding round. The round was led by Boost VC, with participation from Cleo Capital, Manna Ventures, Profluent Capital, and Logan Green, co-founder of Lyft.
Founders' Background and Inspiration
SkinBit was co-founded by Jonathan Benassaya, Bill Dower, and Manuel Colom. Jonathan Benassaya, who serves as the CEO, is known for his previous role as co-founder of the music streaming service Deezer. His personal experience with melanoma, which was discovered by chance during a routine check-up, motivated him to create a more reliable and data-driven method for skin cancer screening. Benassaya stated, "I got lucky, but health shouldn’t rely on luck. No one should die of a cancer you can see."
Innovative Approach to Skin Cancer Screening
SkinBit aims to improve the early detection of skin cancer through its full-body imaging system. The technology allows for a comprehensive record of a patient's skin, which is reviewed by board-certified dermatologists. This approach addresses the challenge of tracking subtle changes in the skin over time, which is difficult with traditional methods.
The startup plans to implement its technology in dermatology practices, longevity clinics, and medical spas. Patients will be able to receive a full-body scan in about 20 minutes, with the images stored for future comparison.
Strategic Use of Funds
The newly acquired funds will be directed towards expanding the availability of SkinBit's technology in clinics across the United States. By placing scanners in strategic locations, the company hopes to make skin cancer screening more accessible and data-driven.
Investor Confidence
The participation of notable investors such as Boost VC and Logan Green underscores the confidence in SkinBit's innovative approach to skin cancer screening. With this funding, SkinBit is positioned to enhance the way dermatological assessments are conducted, potentially reducing the reliance on visual inspections and memory.
Conclusion
SkinBit's recent funding milestone marks a significant step in their mission to improve skin cancer detection. By integrating advanced imaging technology into everyday clinical practice, the company aims to ensure that skin cancer screening becomes more accurate and accessible, ultimately saving lives.